Drug Index


Mechanism :

Ezetimibe has a mechanism of action that differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of HMG-CoA reductase inhibitors.

Indication :

  • Homozygous Familial Hypercholesterolemia
  • Homozygous Sitosterolemia
  • Primary Hyperlipidemia

Contraindications :

Hypersensitivity, Caution if hepatic impairment.

Dosing :

Under 10 years:
Safety and efficacy not established.
Above 10 years:
10 mg orally once every day in combination with atorvastatin or simvastatin, adjunctive diet and in combination with H mg-CoA reductase inhibitors.

Adverse Effect :

Abdominal pain, diarrhea, joint pain, muscle aches, back pain, and sinusitis, hypersensitivity reactions, nausea, myopathy or rhabdomyolysis, pancreatitis, hepatitis

Interaction :

Cholestyramine (Questran), Colestipol (Colestid) and Colesevelam (WelChol), Bile Acid-Binding Drugs: may be used to treat elevated levels of cholesterol, bind to ezetimibe and reduce its absorption from the intestine by about 50%. Therefore, ezetimibe should be taken at least two hours before or 4 hours after administration of these drugs.

Cyclosporine (Gengraf, Neoral): Increases the levels of ezetimibe while ezetimibe increases levels of cyclosporine. Combining both drugs may increase side effects of either drug.
Warfarin: If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDUnlikely to be dialysed. Dose as in normal renal function
HDF/High fluxUnlikely to be dialysed. Dose as in normal renal function
CAV/VVHDUnlikely to be dialysed. Dose as in normal renal function

Hepatic Dose :

Mild hepatic impairment: No dosage adjustment needed.
Moderate and severe hepatic impairment: Due to insufficient data, the manufacturer does not recommend use of this drug in these patients.
01/20/2024 13:52:47 Ezetimibe
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0